Ocular Therapeutix (OCUL) News Today $7.00 -0.25 (-3.45%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$7.12 +0.12 (+1.64%) As of 02/21/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Hussman Strategic Advisors Inc. Takes Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Hussman Strategic Advisors Inc. bought a new stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 105,000 shares of the biopharmaceutical company's sFebruary 22 at 5:03 AM | marketbeat.comOcular Therapeutix CEO gets new compensation packageFebruary 14, 2025 | msn.comLegato Capital Management LLC Trims Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Legato Capital Management LLC trimmed its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 23.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 114,820 shares of the biopharmaceutical comFebruary 14, 2025 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Given Consensus Recommendation of "Moderate Buy" by AnalystsOcular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) has received an average recommendation of "Moderate Buy" from the six ratings firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and five have assigned a buy recommeFebruary 10, 2025 | marketbeat.comRaymond James maintains $19 target on Ocular Therapeutix stockFebruary 6, 2025 | msn.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Insider Sells $49,399.84 in StockFebruary 5, 2025 | insidertrades.comOcular Therapeutix CFO Donald Notman sells $136,238 in stockFebruary 5, 2025 | msn.comDonald Notman Sells 6,301 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) StockOcular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) insider Donald Notman sold 6,301 shares of the company's stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $7.84, for a total transaction of $49,399.84. Following the sale, the insider now directly owns 204,563 shares in the company, valued at $1,603,773.92. This represents a 2.99 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.February 4, 2025 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Insider Sells $86,839.39 in StockOcular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) insider Donald Notman sold 11,119 shares of Ocular Therapeutix stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $7.81, for a total transaction of $86,839.39. Following the transaction, the insider now directly owns 193,444 shares of the company's stock, valued at approximately $1,510,797.64. This trade represents a 5.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.February 4, 2025 | marketbeat.comOcular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual MeetingFebruary 3, 2025 | globenewswire.comOcular Therapeutix IncJanuary 29, 2025 | money.usnews.comOcular Therapeutix (NASDAQ:OCUL) Share Price Passes Below 200-Day Moving Average - Should You Sell?Ocular Therapeutix (NASDAQ:OCUL) Shares Pass Below 200 Day Moving Average - What's Next?January 28, 2025 | marketbeat.comRoundAngle Advisors LLC Takes $1.70 Million Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)RoundAngle Advisors LLC acquired a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 198,456 shares of the biopharmaceutical comJanuary 20, 2025 | marketbeat.comOcular Therapeutix reports inducement grant under Nasdaq listing ruleJanuary 17, 2025 | markets.businessinsider.comOcular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)January 17, 2025 | globenewswire.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from BrokeragesShares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating and six have issued a buy rating on tJanuary 16, 2025 | marketbeat.comOcular Therapeutix, Inc.: Ocular Therapeutix Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI in NPDRJanuary 14, 2025 | finanznachrichten.deOcular Therapeutix shares SOLR-R enrollment progress, next steps AXPAXLIJanuary 14, 2025 | markets.businessinsider.comOcular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDRJanuary 14, 2025 | globenewswire.comEyePoint initiated with a Buy at CitiJanuary 7, 2025 | markets.businessinsider.comEyePoint initiated at buy by Citi on wAMD drug potentialJanuary 7, 2025 | msn.comOcular Therapeutix (OCUL) Receives a Buy from Bank of America SecuritiesJanuary 7, 2025 | markets.businessinsider.comOcular Is Now Thoroughly DeriskedDecember 30, 2024 | seekingalpha.comGeode Capital Management LLC Has $28.46 Million Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Geode Capital Management LLC lessened its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 5.2% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,271,207 shares of the biDecember 27, 2024 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Stock Price Down 2.5% - What's Next?Ocular Therapeutix (NASDAQ:OCUL) Stock Price Down 2.5% - Here's What HappenedDecember 24, 2024 | marketbeat.comBarclays PLC Acquires 138,441 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)Barclays PLC raised its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 37.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 511,522 shares of the biopharmaceutical company's stock after purchasing anDecember 22, 2024 | marketbeat.comState Street Corp Trims Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)State Street Corp trimmed its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 11.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,476,292 shares of the biopharmaceutical company'December 22, 2024 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Given Consensus Rating of "Moderate Buy" by AnalystsOcular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven brokerages that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and six have given a buy recommendation toDecember 22, 2024 | marketbeat.comInvestors might be losing patience for Ocular Therapeutix's (NASDAQ:OCUL) increasing losses, as stock sheds 12% over the past weekDecember 19, 2024 | finance.yahoo.comWellington Management Group LLP Purchases 148,310 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)Wellington Management Group LLP boosted its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 47.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 462,864 shares of the bioDecember 18, 2024 | marketbeat.comFmr LLC Purchases 428,335 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)Fmr LLC lifted its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 7,098.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 434,369 shares of the biopharmaceutical company's stoDecember 14, 2024 | marketbeat.comOcular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)December 13, 2024 | globenewswire.comVerition Fund Management LLC Purchases Shares of 62,501 Ocular Therapeutix, Inc. (NASDAQ:OCUL)Verition Fund Management LLC acquired a new position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 62,501 shares of the biopharmaceutical company's stock, valuDecember 12, 2024 | marketbeat.comOcular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 10, 2024 | globenewswire.comCharles Schwab Investment Management Inc. Has $9.66 Million Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Charles Schwab Investment Management Inc. increased its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 146.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,110,460 shares of the bioDecember 10, 2024 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Point72 Asset Management L.P.Point72 Asset Management L.P. lowered its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 24.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,040,620 shares of the biopharmaDecember 7, 2024 | marketbeat.comPolar Asset Management Partners Inc. Makes New $4.29 Million Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Polar Asset Management Partners Inc. purchased a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 492,900 shares of the biopharmaceutical company's stock, valuedDecember 5, 2024 | marketbeat.comPromising Outlook for Ocular Therapeutix: Buy Rating Supported by Strong Market Demand and Financial ValuationDecember 4, 2024 | markets.businessinsider.comPatient Square Capital LP Makes New Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Patient Square Capital LP bought a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 235,498 shares of theDecember 4, 2024 | marketbeat.comErste Asset Management GmbH Takes $2.05 Million Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Erste Asset Management GmbH acquired a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 235,800 shares of the biopharmaceutical cDecember 4, 2024 | marketbeat.comOcular Therapeutix announces over 300 subjects randomized in SOL-1December 2, 2024 | markets.businessinsider.comOcular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1December 2, 2024 | globenewswire.comBraidwell LP Has $19.49 Million Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Braidwell LP lifted its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 36.3% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,239,770 shares of the biopharmaceutical company's stock after buying an additioNovember 29, 2024 | marketbeat.comKnoll Capital Management LLC Purchases 400,000 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)Knoll Capital Management LLC boosted its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 199.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 600,400 shares of theNovember 29, 2024 | marketbeat.comJeffrey S. Heier Sells 2,948 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) StockNovember 28, 2024 | insidertrades.comAcuta Capital Partners LLC Sells 1,581,059 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)Acuta Capital Partners LLC cut its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 57.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,190,071 shares of the biopharmaceutical company's stockNovember 28, 2024 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Recommendation of "Moderate Buy" from AnalystsOcular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and six have given aNovember 27, 2024 | marketbeat.comOcular Therapeutix(TM) to Participate in December Investor and Scientific ConferencesNovember 26, 2024 | stockhouse.comOcular Therapeutix™ to Participate in December Investor and Scientific ConferencesNovember 26, 2024 | globenewswire.comBanco Santander S.A. Decreases Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Banco Santander S.A. trimmed its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 54.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 172,231 shares of the biopharmaceutical company's stock after selling 205,137 sharNovember 23, 2024 | marketbeat.com Get Ocular Therapeutix News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter. Email Address OCUL Media Mentions By Week OCUL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OCUL News Sentiment▼0.640.60▲Average Medical News Sentiment OCUL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OCUL Articles This Week▼04▲OCUL Articles Average Week Get Ocular Therapeutix News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies KRYS News Today SWTX News Today BHVN News Today RXRX News Today PTCT News Today OGN News Today RARE News Today ALVO News Today RNA News Today ADMA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OCUL) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | SponsoredWarning: China Launches AI Attack on AmericaIf you have any money in AI stocks, pay attention because... According to Louis Navellier, the legendary in...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocular Therapeutix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocular Therapeutix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OCUL Stock Alerts